Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
The funds come from an equity investment by Chinese health firm iCarbonX announced at the beginning of the year as part of a partnership between the companies.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
A company researcher said the new structure could provide the chemical diversity needed to build a set of reagents targeting the full human proteome.
The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.
The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.